Callos Andrew 4

What Happened Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), exercised stock options to acquire 15,857 shares on 2026-05-01 (exercise price $37.63, cost $596,699) and immediately sold those 15,857 shares in an open-market transaction at $65.00 per share for $1,030,705. The transaction produced roughly $434,006 in gross proceeds above the exercise cost (before commissions, taxes, or other fees). The filing also includes a technical line showing the derivative/option conversion at $0, reflecting the option was exercised/converted.

Key Details

• Transaction date: 2026-05-01
• Exercise: 15,857 shares at $37.63 — $596,699 cash paid
• Sale: 15,857 shares at $65.00 — $1,030,705 proceeds
• Approximate gross gain (proceeds minus exercise cost): $434,006 (before fees/taxes)
• Footnote: Option vests over 4 years in equal monthly installments (F1)
• Shares owned after the transactions: not specified in the provided filing summary
• No late filing or 10b5-1 plan is indicated in the provided details

Context This was an option exercise followed by an immediate sale (a cashless or same-day sale), a common way for insiders to realize gains from vested option awards. Such routine sales do not necessarily signal management sentiment about the company’s near-term prospects; they often reflect personal tax or diversification decisions.